Skip to main content

RBM Achieves Milestone in Companion Diagnostic Project with Roche

Premium

Rules-Based Medicine, with its subsidiary Psynova Neurotech, said this week it has achieved a milestone in a companion diagnostic development program with Roche.

Using its DiscoveryMAP protein biomarker discovery platform as well as Psynova's biomarker database, the company identified a biomarker pattern useful in monitoring disease progression and predicting and monitoring the efficacy of a compound in Roche's central nervous system drug pipeline.

Based on the results, Roche has exercised its option to continue commercial development, which could result in additional future milestone and royalty payments to RBM and Psynova.

RBM was acquired last month by Myriad Genetics for $80 million (PM 04/28/2010). Upon announcing the purchase, Myriad director of investor relations and corporate communications Rebecca Chambers cited RBM's biomarker discovery services as a key asset, noting that, among other things, it establishes valuable relationships with pharmaceutical companies that use the platform for companion diagnostic discovery.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.